As an exclusive production in the Chinese pharmaceutical market, OLMETEC PLUS^® is a new-generation compound preparation of an angiotensin II receptor blocker, olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide. Developed and manufactured by Daiichi Sankyo, its commercialization right on the Chinese market is entitled to Simcere.